Overall Status

Completed (1)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Constellation Pharmaceuticals (1)

Molecular Templates, Inc. (1)

Wyeth is now a wholly owned subsidiary of Pfizer (1)

Collaborator

PETHEMA (Program for the Study and Treatment of Haematological Malignances) (1)

Intervention

glycopeptide (1)

mt-3724 phase 1 (1)

mt-3724 phase 2 (1)

pelabresib (1)

piperacillin-tazobactam (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (2)

Observational (1)

Hematological Malignancy

Showing NaN - NaN of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Advanced Malignancies, Solid Tumor, Hematological Malignancy Trial in Canton, Gettysburg, West Valley City (Pelabresib)

Recruiting

Advanced Malignancies
+2 more

Pelabresib

Canton, Ohio
+6 more

Jan 30, 2023

Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724

Terminated

Non-Hodgkin's B-cell Lymphoma
+5 more

MT-3724 Phase 1
MT-3724 Phase 2

Tucson, Arizona
+40 more

Jul 18, 2022

Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus

Completed

Hematological Malignancy
+5 more

Alcalá de Henares, Spain
+11 more

Nov 13, 2009